article thumbnail

Can your LNP manufacturing platform cope with the pace of the mRNA revolution?

Pharmaceutical Technology

Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 billion by 2028. billion by 2028.

article thumbnail

Unlocking the potential of mRNA for the future treatment of rare diseases 

Drug Discovery World

Finally, dosing and timing may be controlled simply by adjusting the amount of mRNA delivered to the cells, rather than relying on inducible systems that are integrated into the genome. The identity of the transcript is confirmed by Sanger sequencing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Improving quality control for CAR T cell therapies

Drug Discovery World

If the gene does not integrate into the genome, the cell will not become a CAR T cell. Furthermore, even if the transgene enters the cell in the correct numbers, the location where the gene integrates into the genome is somewhat random. The gene could also bury itself in a silenced region of the genome, leaving the gene dormant.

article thumbnail

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

These tumor-derived entities are used to derive genomic and proteomic data. However, Dr. Bahassi reported that the selection of CTCs using this method is often not very efficient and the CTC population is usually highly contaminated with leukocytes. Detection of Genomic Alterations from cfDNA: Targeted, Non-Personalized Approaches.